Business Context and Reporting Period
KALA BIO, Inc. (KALA) filed a Form 8-K on September 3, 2026, reporting the entry into a material definitive agreement. The company is incorporated in Delaware and trades on The Nasdaq Capital Market.
Key Financial Metrics
This filing is a Current Report regarding a corporate agreement and does not contain audited financial statements, revenue figures, profit data, cash flow, margins, debt levels, or liquidity metrics. The filing text does not provide a clear value for these financial indicators.
Material Changes and Agreement Terms
On September 3, 2026, KALA entered into an Exclusive Distribution and Reseller Agreement with Virotek, Inc. Key terms include:
- Role: KALA is appointed as the sole and exclusive distributor and reseller of a genetic testing and screening program for ophthalmology in the United States.
- Conditionality: The exclusive appointment is contingent on KALA achieving a specific milestone by September 3, 2027. Failure to meet this milestone (subject to a 30-day cure period) converts the appointment to non-exclusive.
- Responsibilities: KALA handles commercial development; Virotek handles delivery and administration.
- Economics: Net profit is split equally (50/50) between the parties after Virotek recovers the full cost of goods sold. This split is reviewed monthly.
- Term: The initial term is five years, renewable by mutual written agreement.
- Right of First Refusal: KALA holds a right of first refusal on any proposed sale or exclusive license of Ophthalmological Products by Virotek to a third party.
Guidance, Outlook, and Risks
The filing contains forward-looking statements regarding the potential benefits of the agreement, the ability to achieve the 2027 milestone, and potential expansion into additional verticals. Management notes that actual results may differ materially due to risks outlined in other SEC filings. Termination clauses allow for immediate exit in cases of material breach, insolvency, or loss of required licenses/accreditations.
Investor Verification Checklist
- Verify the specific performance milestone required by September 3, 2027, as detailed in Exhibit B of the agreement.
- Confirm the definition of "Net Profit" and "Cost of Goods Sold" within the full text of the agreement to understand the revenue split mechanics.
- Assess the financial health and operational capacity of Virotek, Inc., as the delivery partner.
- Review the company's existing pipeline to determine if this ophthalmology program represents a new vertical or an expansion of current offerings.